ReviewNature2026
Multimodal precision diagnostics in clinical xenotransplantation.
Review in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent breakthroughs in pig-to-human xenotransplantation have successfully prevented hyperacute rejection of kidney, heart, liver and lung xenografts, marking a milestone long considered a critical barrier. However, these major advances also brought new challenges into focus, as immune-mediated graft injuries including antibody-mediated rejection, T cell-mediated rejection and innate immune activation have been observed in most xenotransplantation procedures to date. Detection and management of these injuries remain a critical bottleneck, as conventional histopathology and standard clinical monitoring lack the sensitivity required to identify subclinical injury early enough to guide timely intervention. This diagnostic gap underscores an urgent need for the development of advanced, multimodal precision diagnostic frameworks to enhance immune surveillance, which will be essential for standardizing clinical protocols and enabling pathogenesis-driven therapeutic intervention. This approach will inform both immunosuppressive regimens and future gene editing strategies aimed at engineering rejection-resistant porcine organs, ultimately prolonging graft survival. Broad adoption of such an integrative strategy will be essential to transition xenotransplantation from an experimental intervention into a safe, scalable and patient-centred clinical therapy. In this Review, we synthesize recent progress in xenotransplantation and position multimodal precision diagnostics as a pivotal strategy to address the remaining immunological and clinical barriers to widespread clinical implementation.
Indexed as
Identifiers
42907518What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.